

August 12, 2016

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Sub: Un-audited financial results for the quarter ended June 30, 2016


We are pleased to enclose the un-audited financial results of the Company for the quarter ended June 30, 2016 as approved by the Board of Directors of the Company at its meeting held on August 12, 2016 along with the press release.

This is for your information and record purposes.

Thanking you,

Yours faithfully,

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary



SeQuent Scientific Limited

Corporate Office : 30, 'Galaxy', 1st Main Road, J. P. Nagar 3rd Phase, Bangalore - 560 078. India. Tel: +91 80 4675 0300 Fax: +91 80 4675 0400

Regd. Office : 301, 3rd Floor, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W), Mumbai - 400 604. India. Tel: +91 22 4111 4777 Fax: +91 22 4111 4754

CIN : L99999MH1985PLC036685 | Email : info@sequent.in | www.sequent.in

SeQuent Scientific Announces Q1FY17 Financial Results

Bengaluru, August 12, 2016: SeQuent Scientific Limited, a leading Integrated Pharmaceutical Company with business across Animal Health, Niche Human APIs & Analytical Services today announced its financial results for the first quarter ended June 30th, 2016 (Q1FY17)

Consolidated Financial Performance (Q1FY17 vs Q1FY16)

- Operating revenue was **Rs. 1,768 mn** as compared to **Rs. 1,461 mn** in Q1FY16, **up by 21%**
- EBITDA at **Rs. 92 mn** as compared to **Rs. 186 mn** in Q1FY16
- EBITDA Margin at **5.2%** as against **12.7%** in Q1FY16
- Net Loss at **Rs. 102 mn** as compared to a profit of **INR 0.5 mn** in Q1FY16

While operationally all the businesses have performed well, the profits/margins were impacted due to:

- (a) Lower revenue contribution from Turkey, which is the most profitable market, on account of transition to GMP compliance. The Company has already transitioned 49 products under the new GMP regulations and operations are expected to be on growth track by H2 2017
- (b) One time expenses relating to acquisitions and integration of acquired entities
- (c) Enhanced R&D outlay in Alivira and IPC


Commenting on the Company's performance for Q1FY17, **Manish Gupta, Managing Director** said *"With the recent acquisitions, we have completed the phase 1 of our organization building, which was focused on scale, market-access and capabilities. Our efforts are now focused on consolidation and integration of our operations across multiple geographies. We are pleased to collaborate with eminent industry leaders Dr. George Gunn and Dr. Ruurd Stolp, who have joined the newly formed Global Advisory Board to guide the Alivira team in its quest to be a leading Global Veterinary business from India."*

Operational update

- Alivira – the Animal Health business is shaping up well and now accounts for over 60% of the revenues of Sequent with products being sold in over 55 countries.
- Filed 2 DMFs during the quarter
- Initiated an aggressive research and development program in Alivira with over 25 finished dosage products in various dosage forms including orals, solids, liquids, injectable, and pre-mixes.
 - 40% of these products are potential day 1 launch on expiry of respective patents
 - @40% of these products are integrated with in-house API development

Certified True Copy

For Sequent Scientific Limited


Preetnam Hebbar
Company Secretary

- In Turkey, 49 products under the new GMP has been transitioned

Corporate Actions

- Completed acquisition of 70% stake in Interchange Indústria e Comércio de Produtos Veterinários S.A. Brazil ("Interchange") to foray into highly attractive and fast growing Brazilian animal health market. Interchange (tradename - Evance) is amongst the 'Top 10' Brazilian Companies in the veterinary health space with over 25 registered products consisting of antimicrobials, parasiticides, sanitizers and products largely in the poultry and swine segments.
- Completed acquisition of 60% stake in Vila Vina Participações ("VVP") which owns Karizoo Spain, Phytosolutions Spain, Covivet Spain and Karizoo Mexico to reinforce our European presence along with an EU approved manufacturing base and strong R&D capabilities. With presence in over 14 countries, VVP has 12 marketing authorizations in Spain, 65 in rest of European Union, 25 in Mexico and 15 in MENA region with a pipeline of 3 products under registration in EU. 25 products are under development in the areas of anesthetic gas, oral solutions, oral powders, oral suspensions and drug premix products

Global Advisory Board

The Company also announced the formation of a 'Global Advisory Board' with the induction of Dr. George Gunn and Dr. Ruurd Stolp as its founding members to facilitate and guide the Alivira team in its quest to be a leading Global Veterinary business from India.

Dr. George Gunn has been the President and CEO of Novartis Animal Health business till the time of its divestiture to Elanco and President and CEO of Novartis Consumer Health Division prior to that. He also managed the full scope of integration planning for the sale of Novartis Animal Health business to Eli Lilly. Dr. Gunn is a Doctorate in Veterinary Medicine and Surgery.


Dr. Ruurd Stolp has been a Member of the Strategic Advisory Board of Elanco for 5 years. Prior to that, he spent 21 years with Intervet, including the last 6 years as President. Dr. Stolp is also a Doctorate in Veterinary Medicine.

Both Dr. Gunn's and Dr. Stolp's extensive global experience in the animal health industry would add immense value to Alivira's strategy and direction and ensure that the Company is ahead of the curve in addressing and executing opportunities that the market presents.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has nine manufacturing facilities based in India, Turkey, Spain and Brazil with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary

Contact Details

Kannan P R

Chief Financial Officer

Tel: +91 80 4657 0327

Kannan.pr@sequent.in

Ankit Gupta

Christensen Investor Relations

Tel : +91 22 4215 0210

ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle',

Plot No. E7, Road No. 22,

Wagle Industrial Area, Thane (W),

Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529

NSE: SEQUENT


ISIN: INE807F01027

REUTERS: SEQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED


1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the Quarter ended June 30, 2016 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:
 - i. Alivira Animal Health Australia Pty Ltd;
 - ii. Alivira Animal Health Limited Ireland;
 - iii. Alivira Animal Health Limited;
 - iv. Alivira Saude Animal Brasil Participacoes Ltda.
 - v. Elysian Life Sciences Private Limited;
 - vi. Fendigo BV;
 - vii. Fendigo SA;
 - viii. Indo Phyto Chemicals Private Limited;
 - ix. N-Vet AB;
 - x. Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
 - xi. SeQuent Antibiotics Private Limited;
 - xii. Sequent European Holdings Limited;
 - xiii. SeQuent Global Holdings Limited;
 - xiv. SeQuent Penems Private Limited;
 - xv. SeQuent Pharmaceuticals Private Limited;
 - xvi. SeQuent Research Limited;
 - xvii. Sequent Scientific Pte. Ltd.
 - xviii. Topkim-Topkapi Ilac Premiks San. ve Tic. A.S.

10,

Deloitte
Haskins & Sells

4. We did not review the interim financial results of five subsidiaries, whose interim results reflect total revenues of Rs. 4,006.59 lakhs for the Quarter ended June 30, 2016, and total loss after tax of Rs. 108.98 lakhs and total comprehensive loss of Rs.108.98 lakhs for the Quarter ended June 30, 2016, as considered in the consolidated financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.
5. The consolidated financial results includes the interim financial results of eleven subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 1,269.00 lakhs for the Quarter ended June 30, 2016, total loss after tax of Rs.184.92 lakhs and total comprehensive loss of Rs. 184.92 lakhs for the Quarter ended June 30, 2016, as considered in the consolidated financial results.
6. Based on our review conducted as stated above and based on the consideration of the reports of the other auditors referred to in paragraph 4 above and except for the possible effects of the matter described in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We have not reviewed the financial results and other financial information for the Quarter ended June 30, 2015 which have been presented solely based on the financial information compiled by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



V Srikumar
Partner
(Membership No.84494)

Bangalore, August 12, 2016
VS/SPK/JKS/2016

Sequent

SEQUENT SCIENTIFIC LIMITED

(Rs. in Lakhs)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

Particulars	3 months ended 30-June-2016	Corresponding 3 months ended in the previous year 30-June 2015 (Refer note 4)
	UNAUDITED	UNAUDITED
1. Income from operations		
a. Net sales / income from operations (net of excise duty)	17,473.10	14,433.36
b. Other operating income	207.60	179.33
Total income from operations (net)	17,680.70	14,612.69
2. Expenses		
a. Cost of materials consumed	6,409.00	5,179.50
b. Purchase of stock-in-trade	2,642.60	2,436.10
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(402.60)	208.20
d. Employee benefits expenses	3,098.40	1,910.40
e. Depreciation and amortisation expenses	1,424.20	927.40
f. Other expenses	5,012.70	3,015.83
Total expenses	18,184.30	13,677.43
3. Profit/(loss) from operations before other income, finance costs and exceptional items (1-2)	(503.60)	935.26
4. Other income	232.90	245.96
5. Profit/(loss) from ordinary activities before finance cost and exceptional items (3±4)	(270.70)	1,181.22
6. Finance cost	875.00	1,106.80
7. Profit/(loss) from ordinary activities after finance cost but before exceptional items (5±6)	(1,145.70)	74.42
8. Exceptional items- Expense/(Income)	-	-
9. Profit/(loss) from ordinary activities before tax (7±8)	(1,145.70)	74.42
10. Tax expense	40.80	93.67
11. Net profit/(loss) for the period (11±12)	(1,186.50)	(19.25)
12. Share of profit/(loss) of associates	-	-
13. Non-controlling interest	(161.60)	(23.91)
14. Net profit/(loss) after taxes, minority interest and share of profit/(loss) of associates (11 ±12±13)	(1,024.90)	4.66
15. Other comprehensive income	1,071.29	14,904.97
16. Total comprehensive income	46.39	14,909.63
17. Paid-up equity share capital (Face Value per share Rs.2 each)	4,764.70	4,126.18
18. Earnings per share (of Rs. 2 each) (not-annualised)		
Basic (Rs.)	(0.43)	0.003
Diluted (Rs.)	(0.43)	0.003
See accompanying note to the financial results		



Notes:

1. The unaudited consolidated financial results has been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on August 12, 2016. The statutory auditors have carried out limited review of the financial results for the quarter ended June 30, 2016.

2. Segment Results


The Company has identified Pharmaceuticals and Analytical Services as its business segments. Segments have been identified taking in to account the nature of products, the differing risks and returns, the organisational structure and the internal reporting system.

Particulars	Quarter Ended	
	3 months ended 30-June-2016	Corresponding 3 months ended in the previous year 30-June 2015 (Refer note 4)
	UNAUDITED	UNAUDITED
1.Segment Revenue		
a) Pharmaceuticals	17,501.20	14,357.58
b) Analytical Services	179.50	255.11
Total	17,680.70	14,612.69
Less : Inter Segment Revenue	-	-
Net Sales /Income from Operations	17,680.70	14,612.69
2.Segment Results		
Profit or (Loss) before Tax and Interest from Each Segment		
a) Pharmaceuticals	(548.02)	849.81
b) Analytical Services	44.42	85.45
Total	(503.60)	935.26
Less (i) Finance Cost	875.00	1,106.80
(ii) Other unallocable expenditure net off unallocable (income)	(232.90)	(245.96)
Total Profit / (Loss) Before Tax	(1,145.70)	74.42
3.Segment Assets		
a) Pharmaceuticals	111,618.68	99,560.95
b) Analytical Services	2,061.62	1,459.06
c) Unallocated	50,141.40	40,501.13
Total	163,821.70	141,521.14
4.Segment Liabilities		
a) Pharmaceuticals	58,887.92	44,436.25
b) Analytical Services	1,386.28	1,363.37
c) Unallocated	968.50	696.21
Total	61,242.70	46,495.83

3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended 31 March 2016 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

4. The financial results for the quarter ended 30 June 2015 is not subject to limited review. However the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs. The profit reconciliation is given below:

Net profit reconciliation	Quarter ended 30-June 2015
Net profit / (loss) after tax as per previous GAAP (Indian GAAP)	73.59
Add/(Less): Fair value of mutual funds	3.96
Add/(Less): Amortization of leasehold land	28.00
Add/(Less): Fair value of derivatives	(28.62)
Add/(Less): Exchange loss on contingent consideration	(48.86)
Add/(Less): Employee benefit expenses (share based payments, Actuarial gain/loss)	(10.80)
Add/(Less): Others	(12.61)
Net profit / (loss) after tax as per Ind AS [A]	4.66
Other Comprehensive Income (OCI):	
Add/(Less): Exchange differences on translation of foreign operation	1,181.59
Add/(Less): Re-measurement gains/ (losses) on defined benefit plans	(7.85)
Add/(Less): Fair value of equity investment through OCI	13,731.23
Sub-total [B]	14,904.97
Total comprehensive income for the period [A+B]	14,909.63



5. During the quarter, the Company's step down subsidiary Alivira Animal Health Limited, Ireland incorporated a wholly owned subsidiary Alivira Saude Animal Brasil Participacoes LTDA, Brazil.

6. On July 1, 2016, the Company's step down subsidiary Alivira Animal Health Limited, Ireland acquired 60% stake in Vila Vina Participacions, S.L., Spain, which owns Karizoo S.A., Spain, Comercial Vila Veterinaria De Lleida S.L. (Covivet), Spain, Phytotherapic Solutions S.L., Spain and Karizoo Mexico, S.A. de CV, Mexico.


7. Subsequent to the quarter end, the Company's step down subsidiary Alivira Saude Animal Brasil Participacoes LTDA, Brazil, acquired 70% stake in Interchange Veterinária Indústria E Comércio S.A. Brazil.

8 Information on Standalone Results:

	Quarter Ended	
	3 months ended 30-June-2016	Corresponding 3 months ended in the previous year 30-June 2015 (Refer note 4)
Total Income from operations (net)	8,656.65	10,710.00
Profit before Tax	(191.70)	365.24
Profit after Tax	(191.70)	365.24
Total comprehensive income	1,163.50	14,097.17

9. Figures for previous periods have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

Place : Bengaluru
Date : August 12, 2016



For Sequent Scientific Limited

Manish Gupta
Manish Gupta
Managing Director



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company") for the Quarter ended June 30, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We have not reviewed the financial results and other financial information for the Quarter ended June 30, 2015 which have been presented solely based on the financial information compiled by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)


V. Srikumar
Partner
(Membership No. 84494)

Bangalore. Aug 12, 2016

Sequent

Creating Reliability for the Future

SEQUENT SCIENTIFIC LIMITED

(Rs. in Lakhs)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

Particulars	3 months ended 30-Jun-16	Corresponding 3 months ended 30- Jun-15 (Refer Note.3)
	UNAUDITED	UNAUDITED
1. Income from operations		
a Net sales / income from operations (net of excise duty)	8,492.23	10,303.50
b Other operating income	164.42	406.50
Total income from operations (net)	8,656.65	10,710.00
2. Expenses		
a Cost of materials consumed	4,537.84	3,977.30
b Purchase of stock-in-trade	258.93	2,029.01
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	(21.81)	448.60
d Employee benefits expenses	1,139.09	971.65
e Depreciation and amortisation expenses	568.31	520.90
f Other expenses	2,546.73	2,000.46
Total expenses	9,029.09	9,947.92
3. Profit/(loss) from operations before other income, finance costs and exceptional items (1-2)	(372.44)	762.08
4. Other income	396.72	319.76
5. Profit/(loss) from ordinary activities before finance cost and exceptional items (3±4)	24.28	1,081.84
6. Finance cost	215.98	716.60
7. Profit/(loss) from ordinary activities after finance cost but before exceptional items (5±6)	(191.70)	365.24
8. Exceptional items- expense/(income)	-	-
9. Profit/(loss) from ordinary activities before tax (7±8)	(191.70)	365.24
10. Tax expense	-	-
11. Net profit/(loss) from ordinary activities after tax (9±10)	(191.70)	365.24
12. Other comprehensive income	1,355.20	13,731.93
13. Total comprehensive income (11±12)	1,163.50	14,097.17
14. Paid-up equity share capital (Face Value per share Rs.2 each)	4,764.70	4,126.18
15 Earnings per share (of Rs. 2 each) (not-annualised)		
Basic (Rs.)	(0.08)	0.21
Diluted (Rs.)	(0.08)	0.19
See accompanying note to the financial results		



Notes:

1. The unaudited financial results has been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on August 12, 2016. The statutory auditors have carried out limited review of the financial results for the quarter ended June 30, 2016.

2. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended 31 March 2016 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

3. The financial results for the quarter ended 30 June 2015 is not subject to limited review. However the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs. The profit reconciliation is given below:

Net profit reconciliation	Quarter ended 30-June 2015
Net profit / (loss) after tax as per previous GAAP (Indian GAAP)	380.80
Add/(Less): Fair value of mutual funds	3.96
Add/(Less): Fair value of derivatives	(0.17)
Add/(Less): Employee benefit expenses (share based payments, Actuarial gain/loss)	(19.35)
Net profit / (loss) after tax as per Ind AS [A]	365.24
Other Comprehensive Income (OCI):	
Add/(Less): Re-measurement gains/ (losses) on defined benefit plans	0.70
Add/(Less): Fair value of equity investment through OCI	13,731.23
Sub-total [B]	13,731.93
Total comprehensive income for the period [A+B]	14,097.17

4. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

5. During the quarter, the Company's step down subsidiary Alivira Animal Health Limited, Ireland incorporated a wholly owned subsidiary Alivira Saude Animal Brasil Participacoes LTDA, Brazil.

6. On July 1, 2016, the Company's step down subsidiary Alivira Animal Health Limited, Ireland acquired 60% stake in Vila Vina Participacions, S.L., Spain, which owns Karizoo S.A., Spain, Comercial Vila Veterinaria De Lleida S.L. (Covivet), Spain, Phytotherapeutic Solutions S.L., Spain and Karizoo Mexico, S.A. de CV, Mexico.

7. Subsequent to the quarter end, the Company's step down subsidiary Alivira Saude Animal Brasil Participacoes LTDA, Brazil, acquired 70% stake in Interchange Veterinária Indústria E Comércio S.A. Brazil.

8. Figures for previous periods have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

Place : Bengaluru

Date : August 12, 2016



For Sequent Scientific Limited

Manish Gupta

Manish Gupta
Managing Director

